A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

I4V-MC-JAHH -

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Systemic Lupus Erythematosus
What the trial is testing?
Baricitinib
Could I receive a Placebo?
Yes
Enrollment Goal
314
Trial Dates
Mar 24, 2016 - Nov 9, 2017
How long will I be in the trial?
Your participation could last up to 34 weeks and include 10 visits to the study center.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.